This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watanabe, H.
Right arrow Articles by Nagatake, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watanabe, H.
Right arrow Articles by Nagatake, T.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2001, p. 3775-3777, Vol. 39, No. 10
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.10.3775-3777.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Low Concentrations of Mupirocin in the Pharynx following Intranasal Application May Contribute to Mupirocin Resistance in Methicillin-Resistant Staphylococcus aureus

Hiroshi Watanabe,1,* Hironori Masaki,1 Norichika Asoh,1 Kiwao Watanabe,1 Kazunori Oishi,1 Shinobu Kobayashi,2 Akiyoshi Sato,3 Rinya Sugita,4 and Tsuyoshi Nagatake1

Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University,1 and Departments of Internal Medicine2 and Microbiology,3 Kyorin Hospital, Nagasaki, and Sugita Otorhinolaryngologic Clinic, Chiba,4 Japan

Received 21 May 2001/Returned for modification 11 July 2001/Accepted 24 July 2001

We describe a patient with methicillin-resistant Staphylococcus aureus (MRSA) colonizing the pharynx. The MIC of mupirocin was 0.25 µg/ml before treatment and increased after treatment to 8 µg/ml. Using pulsed-field gel electrophoresis, we confirmed that the genotypes of MRSA that colonized the pharynx before and after the use of mupirocin were identical. We measured the delivery of mupirocin to the pharynx in three normal volunteers and two patients. Low concentrations of mupirocin were present in the pharynx in all cases 10 min to 3 days after intranasal application. Our data suggested that low concentrations of the drug in the pharynx after intranasal application of mupirocin ointment might explain the selection of mupirocin resistance in MRSA.


* Corresponding author. Mailing address: Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. Phone: 81 (95) 849-7842. Fax: 81 (95) 849-7843. E-mail: h-wata{at}net.nagasaki-u.ac.jp.


Journal of Clinical Microbiology, October 2001, p. 3775-3777, Vol. 39, No. 10
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.10.3775-3777.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Nilsson, P., Ripa, T. (2006). Staphylococcus aureus Throat Colonization Is More Frequent than Colonization in the Anterior Nares.. J. Clin. Microbiol. 44: 3334-3339 [Abstract] [Full Text]  
  • Hurdle, J. G., O'Neill, A. J., Chopra, I. (2005). Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob. Agents Chemother. 49: 4821-4833 [Full Text]  
  • Critchley, I. A., Young, C. L., Stone, K. C., Ochsner, U. A., Guiles, J., Tarasow, T., Janjic, N. (2005). Antibacterial Activity of REP8839, a New Antibiotic for Topical Use. Antimicrob. Agents Chemother. 49: 4247-4252 [Abstract] [Full Text]  
  • Ochsner, U. A., Young, C. L., Stone, K. C., Dean, F. B., Janjic, N., Critchley, I. A. (2005). Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase. Antimicrob. Agents Chemother. 49: 4253-4262 [Abstract] [Full Text]  
  • Rouse, M. S., Rotger, M., Piper, K. E., Steckelberg, J. M., Scholz, M., Andrews, J., Patel, R. (2005). In Vitro and In Vivo Evaluations of the Activities of Lauric Acid Monoester Formulations against Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 3187-3191 [Abstract] [Full Text]  
  • Wertheim, H. F. L., Verveer, J., Boelens, H. A. M., van Belkum, A., Verbrugh, H. A., Vos, M. C. (2005). Effect of Mupirocin Treatment on Nasal, Pharyngeal, and Perineal Carriage of Staphylococcus aureus in Healthy Adults. Antimicrob. Agents Chemother. 49: 1465-1467 [Abstract] [Full Text]  
  • Hurdle, J. G., O'Neill, A. J., Ingham, E., Fishwick, C., Chopra, I. (2004). Analysis of Mupirocin Resistance and Fitness in Staphylococcus aureus by Molecular Genetic and Structural Modeling Techniques. Antimicrob. Agents Chemother. 48: 4366-4376 [Abstract] [Full Text]  
  • Kruszewska, D., Sahl, H.-G., Bierbaum, G., Pag, U., Hynes, S. O., Ljungh, A. (2004). Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 54: 648-653 [Abstract] [Full Text]  
  • Chaves, F., Garcia-Martinez, J., de Miguel, S., Otero, J. R. (2004). Molecular Characterization of Resistance to Mupirocin in Methicillin-Susceptible and -Resistant Isolates of Staphylococcus aureus from Nasal Samples. J. Clin. Microbiol. 42: 822-824 [Abstract] [Full Text]  
  • Hurdle, J. G., O'Neill, A. J., Chopra, I. (2004). The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J Antimicrob Chemother 53: 102-104 [Abstract] [Full Text]  
  • Kokai-Kun, J. F., Walsh, S. M., Chanturiya, T., Mond, J. J. (2003). Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model. Antimicrob. Agents Chemother. 47: 1589-1597 [Abstract] [Full Text]  
  • Horii, T., Morita, M., Muramatsu, H., Muranaka, Y., Kanno, T., Maekawa, M. (2003). Effects of mupirocin at subinhibitory concentrations on flagella formation in Pseudomonas aeruginosa and Proteus mirabilis. J Antimicrob Chemother 51: 1175-1179 [Abstract] [Full Text]